Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment

ClinicalTrials.gov ID: NCT07444567

Public ClinicalTrials.gov record NCT07444567. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Aug 20, 2026, 1:30 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study With Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit From Continued Treatment

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The rationale of the roll-over study (ROSY) is to provide continuous access to study treatment for participants who have completed or exited a parent study and are deemed appropriate for continued benralizumab treatment, as judged by the Investigator, while monitoring long-term safety and tolerability of benralizumab.

Study identification

NCT ID: NCT07444567
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 230 participants

Conditions and interventions

Conditions

Interventions

Benralizumab Drug

Drug

Eligibility (public fields only)

Age range: 6 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 23, 2026
Primary completion: Jan 2, 2030
Completion: Jan 2, 2030
Last update posted: Aug 18, 2026

2026 – 2030

United States locations

U.S. sites: 8
U.S. states: 8
U.S. cities: 8

Facility	City	State	ZIP	Site status
Research Site	Aurora	Colorado	80045	Not yet recruiting
Research Site	Bethesda	Maryland	20892	Not yet recruiting
Research Site	Ann Arbor	Michigan	48105	Not yet recruiting
Research Site	Northfield	New Jersey	08225	Not yet recruiting
Research Site	The Bronx	New York	10459	Not yet recruiting
Research Site	Durham	North Carolina	27705	Not yet recruiting
Research Site	Cleveland	Ohio	44106	Not yet recruiting
Research Site	Salt Lake City	Utah	84107	Not yet recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07444567, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2026 · Synced Aug 20, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07444567 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →